RecruitingPhase 3

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

France132 participantsStarted 2025-12-08

Plain-language summary

CIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the survival of patients suffering from MSI-H/dMMR locally advanced or metastatic oeasogastric adenocarcinoma treated by a bi-immunotherapy (experimental arm) versus standard current treatment (FOLFOX/XELOX + nivolumab : standard arm).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. ≥ 50 years of age and has not had menses for greater than 1 year.
✓. Amenorrheic for ≥ 2 years without a hysterectomy and bilateral oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation.
✓. Status is post-hysterectomy, bilateral oophorectomy, or tubal ligation.

What they're measuring

Survival of patients

Timeframe: at least 2 years

Trial details

NCT IDNCT06346197

SponsorCentre Leon Berard

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-05-15

Contact for this trial

Christelle DE LA FOUCHARDIERE, MD

04 91 22 35 03 delafouchardierec@ipc.unicancer.fr

View on ClinicalTrials.gov More Gastric Cancer trials